|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in aduhs with refractory and relapsed acute leukemias 显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，7： | 1 |
| 2 | Combined methyitransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS,CMMoL and AML:clinical response,histone acetylation and DNA damage显示文摘 | Gore SD Jiemjit A Silverman LB | 2006 | Blood2006，108，11： | 1 |
| 3 | p21 (WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage显示文摘 | Jiemjit A Fandy TE Carraway H | | 0，，25： | 1 |
| 4 | p21(WAF1/CIP1)induction by 5-azacytosine nucleosides requires DNA damage显示文摘 | Jiemjit A Fandy TE Carraway H | 2008 | Oncogene2008，27，25： | 1 |
| 5 | Phase 1 and pharmacologic study of MS-275,a histone deacetylase inhibitor,in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel J B | 2007 | Blood2007，109，7： | 1 |
| 6 | Phase 1 and pharmacologic study of MS-275,a histone deacetylase inhibitor,in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，： | 1 |
| 7 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias 显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，： | 1 |
| 8 | Phaseland pharmacologic study of MS-275, a histone deacetylase inhibitors, in adults with refractory and relapsed acute leukemias 显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，7： | 1 |
| 9 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，7： | 1 |
| 10 | p21 (WAF1/ CIP1)induction by 5-azacytosine nucleosides requires DNA damage显示文摘 | Jiemjit A Fandy TE Carraway H | 2008 | Oncogene2008，27，25： | 1 |
| 11 | Phase 1 and pharmacologicstudy of MS - 275, a histone deacetylase inhibitor, in adults withrefractory and relapsed acute leukemias 显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，7： | 1 |
| 12 | Phase 1 and pharmacologic study of MS-275, a histone deaeetylase inhibitor, in adults with refractory and relapsed acute leukemias 显示文摘 | GOJO I JIEMJIT A TREPEL J B | 2007 | Blood2007，109，7： | 1 |
| 13 | p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage 显示文摘 | Jiemjit A Fandy TE Carraway H | 2008 | Oncogene2008，27，25： | 1 |
| 14 | Phase 1 and pharmacologic study of MS-275,a histone deacetylase inhibitor,in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，7： | 1 |
| 15 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel J B | 2007 | Blood2007，109，7： | 1 |
| 16 | Phase 1 and pharma-cologic study of MS-275,a histone deacetylase inhi-bitor,in adults with refractory and relapsed acute leu-kemias 显示文摘 | GOJO I JIEMJIT A KARP J | 2007 | Blood2007，109，7： | 1 |
| 17 | Combined methyltransferase/histone deacetylase inhibition with 5-azaeitidine and MS- 275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage显示文摘 | Core S D Jiemjit A Silverman L B | 2006 | Blood2006，108，： | 1 |
| 18 | p21(WAF1/CIP1)induction by 5-azacytosine nucleosides requires DNA damage显示文摘 | Jiemjit A Fandy TE Carraway H | | 0，，25： | 1 |
| 19 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias显示文摘 | Gojo I Jiemjit A Trepel JB | 2007 | Blood2007，109，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员